Fixed combination of bimatoprost and timolol in patients with primary open-angle glaucoma or ocular hypertension with inadequate IOP adjustment

Figures & data

Table 1 Patient demographics at baseline (n = 1862)

	Mean ± SD (range)	n	%
Age (years)	67.1 ± 11.8 (6–95)	1811
Male		793	42.6
Female		1069	57.4
Elevated IOP first diagnosed previous to trial (years)	7.7 ± 6.2 (1–71)	1300
Corneal thickness (μm)
Right eye	550.5 ± 69.8 (400–1600)	601
Left eye	552.4 ± 76.1 (400–1730)	603
Risk factors
High IOP		1509	81.0
Family history of glaucoma		312	16.8
Visual field defects
Mild		1454*	57.0
Moderate		718*	28.0
Advanced		381*	15.0
Missing information		1171*	n/a
Optic disc defects
Mild		1235*	45.0
Moderate		920*	34.0
Advanced		566*	21.0
Missing information		1003*	n/a

* Note: Refers to number of eyes; n = 3724 eyes.

Abbreviations: IOP, intraocular pressure; n/a, not available; SD, standard deviation.

Table 2 Prior medications taken by >1% of patients, among those whose prior therapy was documented (n = 1719)*

Medication	n	%	Active agent(s)
Xalatan^®	286	16.6	Latanoprost (0.005%)
Tim^®-Ophtal^®	195	11.3	Timolol (0.1%, 0.25%, 0.5%)
Timolol	185	10.8	Timolol (0.1%, 0.25%, 0.5%)
Cosopt^®	175	10.2	Timolol (0.5%), dorzolamide (0.2%)
Lumigan^®	146	8.5	Bimatoprost (0.03%)
Azopt^®	144	8.4	Brinzolamide (1%)
Travatan^®	135	7.9	Travoprost (0.004%)
Xalacom^®	125	7.3	Timolol (0.5%), latanoprost (0.005%)
Trusopt^®	74	4.3	Dorzolamide (2%)
Alphagan^®	71	4.1	Brimonidine (0.1%, 0.15%)
DuoTrav^®	70	4.1	Timolol (0.5%), travoprost (0.004%)
Betamann^®	59	3.4	Metipranolol (0.1%, 0.3%, 0.6%)
Timomann^®	54	3.1	Timolol (0.1%, 0.25%, 0.5%)
Combigan^®	47	2.7	Timolol (0.5%), brimonidine (0.2%)
Arutimol^®/-uno	41	2.4	Timolol (0.25%, 0.5%)
NyoGel^®	31	1.8	Timolol (0.1%)
Timo-comod^®	30	1.7	Timolol (0.25%, 0.5%)
Clonid-Ophtal^®	28	1.6	Clonidine (0.063%, 0.125%)
Vistagan^®	25	1.5	Levobunolol (0.1%, 0.25%, 0.5%)
Timohexal^®	21	1.2	Timolol (0.1%, 0.25%, 0.5%)

* Note: Individual patients could have received more than one category of intraocular pressure-lowering medication.

Figure 1 Mean IOP (± SD) at baseline, six weeks, and three months, for right and left eyes in the total population.

Note: * P < 0.0001 compared with baseline.
Abbreviation: IOP, intraocular pressure.

Figure 2 Percentage of right and left eyes achieving various IOP targets at three months.

Abbreviation: IOP, intraocular pressure.